These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 406999)

  • 41. Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients.
    Chiodini PG; Liuzzi A; Muller EE; Botalla L; Cremascoli G; Oppizzi G; Verde G; Silvestrini F
    J Clin Endocrinol Metab; 1976 Aug; 43(2):356-63. PubMed ID: 950367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hormone secretion by dispersed cell cultures of human pituitary adenomas: effects of theophylline, thyrotropin-releasing hormone, somatostatin, and 2-bromo-alpha-ergocryptine.
    Adams EF; Brajkovich IE; Mashiter K
    J Clin Endocrinol Metab; 1979 Jul; 49(1):120-6. PubMed ID: 109461
    [No Abstract]   [Full Text] [Related]  

  • 43. The effect of dexamethasone on TSH and prolactin secretion after TRH stimulation.
    Dussault JH
    Can Med Assoc J; 1974 Dec; 111(11):1195-7. PubMed ID: 4215558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prolactin response to TRH during inhibition of puerperal lactation with ergolinic drugs.
    Crosignani PG; Lombroso GC; Trojsi L; Caccamo A; Reschini E; Peracchi M
    Horm Metab Res; 1977 Mar; 9(2):163-4. PubMed ID: 405303
    [No Abstract]   [Full Text] [Related]  

  • 45. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.
    Moses AC; Molitch ME; Sawin CT; Jackson IM; Biller BJ; Furlanetto R; Reichlin S
    J Clin Endocrinol Metab; 1981 Oct; 53(4):752-8. PubMed ID: 6793607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of bromocryptine on the secretion of thyrotropic hormone, triiodothyronine, and thyroxine in patients with hypothyroidism].
    Felt V; Nedvídková J
    Vnitr Lek; 1977 Sep; 23(9):868-70. PubMed ID: 411252
    [No Abstract]   [Full Text] [Related]  

  • 47. [Results of CB 154 in the treatment of acromegaly in France (author's transl)(proceedings)].
    Bricaire H
    Ann Endocrinol (Paris); 1976; 37(4):305-8. PubMed ID: 1037363
    [No Abstract]   [Full Text] [Related]  

  • 48. Long-term treatment with lisuride suppresses prolactin but not thyrotropin secretion.
    Barreca T; Pescatore D; Magnani G; Giberti C; Martorana G; Marabini A; Rolandi E
    Horm Metab Res; 1982 Sep; 14(9):501-2. PubMed ID: 6815043
    [No Abstract]   [Full Text] [Related]  

  • 49. Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients.
    De Marinis L; Mancini A; Zuppi P; Fiumara C; Conte G; Sammartano L; Fabrizi ML; Valle D
    Exp Clin Endocrinol Diabetes; 1996; 104(1):67-71. PubMed ID: 8750573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thyrotropin-releasing hormone.
    Jackson IM
    N Engl J Med; 1982 Jan; 306(3):145-55. PubMed ID: 6798440
    [No Abstract]   [Full Text] [Related]  

  • 51. [Effects on growth hormone secretion of a new somatostatin analogue (SMS 201-995) and nonspecific releasing hormones in patients with acromegaly].
    Candrina R
    Medicina (Firenze); 1988; 8(2):180-1. PubMed ID: 3147351
    [No Abstract]   [Full Text] [Related]  

  • 52. Neurotransmitter control of growth hormone, thyrotropin and prolactin secretion.
    Muller EE; Genazzani AR; Cocchi D; Casanueva F; Camanni F; Massara F; Molinatti GM
    J Endocrinol Invest; 1980; 3(3):331-3. PubMed ID: 6107316
    [No Abstract]   [Full Text] [Related]  

  • 53. Dynamics of growth hormone secretion in untreated acromegaly.
    Dash RJ; Rao NS; Sriprakash ML; Sialy R
    J Assoc Physicians India; 1987 May; 35(5):341-3. PubMed ID: 3121582
    [No Abstract]   [Full Text] [Related]  

  • 54. [TRH-stimulated growth hormone secretion in acromegaly. Therapeutic results with 188 patients].
    Eversmann T; Lüdeke U; Fahlbusch R; von Werder K
    Dtsch Med Wochenschr; 1986 Jul; 111(28-29):1091-6. PubMed ID: 3089753
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Prolactin secretion on the administration of thyrotropin-releasing hormone in patients with thyroid function disorder (author's transl)].
    Nedvídková J; Felt V
    Cas Lek Cesk; 1975 Aug; 114(33):1011-3. PubMed ID: 809136
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical experience with hypothalamic releasing hormones. 1. Thyrotropin-releasing hormone.
    Gual C; Kastin AJ; Schally AV
    Recent Prog Horm Res; 1972; 28():173-200. PubMed ID: 4631752
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-term treatment of acromegaly with bromocryptine: postprandial HGH levels and response to TRH and glucose administration.
    Benker G; Zäh W; Hackenberg K; Hamburger B; Günnewig H; Reinwein D
    Horm Metab Res; 1976 Jul; 8(4):291-5. PubMed ID: 182633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum levels of thyrotropin, prolactin, growth hormone, triiodothyronine and thyroxine after oral administration of thyrotropin releasing hormone in hypothyroid and hyperthyroid patients.
    Nedvídková J; Felt V
    Endokrinologie; 1976; 68(2):175-82. PubMed ID: 827434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Feasibility of suppressing and reinitiating lactation in women with premature infants.
    Canales ES; Lasso P; Murrieta S; Fonseca E; Soria J; Zárate A
    Am J Obstet Gynecol; 1977 Jul; 128(6):695-7. PubMed ID: 406790
    [No Abstract]   [Full Text] [Related]  

  • 60. [Bromocriptine therapy in acromegaly (author's transl)(proceedings)].
    Schaison G; Mowszowicz I
    Ann Endocrinol (Paris); 1976; 37(4):297-8. PubMed ID: 1037359
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.